DBV Technologies Reports Q3 2025 Financial Results with Increased Net Loss and Operating Income

DBV Technologies S.A. reported its financial results for the third quarter of 2025, revealing a net loss of $33.2 million, compared to a loss of $30.4 million in the same period last year. The company's operating income for the quarter was $2.8 million, a significant increase from $1.1 million in the prior year, primarily driven by a rise in research tax credits, which increased by 159% to $2.8 million. For the nine months ending September 30, 2025, DBV's net loss totaled $102.1 million, up from $90.9 million in the same period of 2024, with a net loss per share of $0.82 compared to $0.95.

The company experienced a notable increase in operating expenses, which rose to $37.1 million for the third quarter, up 18% from $31.4 million in the previous year. This increase was largely attributed to higher research and development costs, which climbed by 21% to $28.6 million, reflecting ongoing clinical trials and regulatory activities related to the Viaskin Peanut patch. Sales and marketing expenses also surged by 127% to $1.2 million, as the company ramped up pre-commercialization efforts in North America.

DBV Technologies has made significant strides in its clinical programs, particularly with the Viaskin Peanut patch, which is being developed for children with peanut allergies. The company is currently conducting a Phase 3 study, VITESSE, for children aged four to seven, with topline results expected in the fourth quarter of 2025. Additionally, the company initiated the COMFORT Toddlers supplemental safety study for children aged one to three, which is anticipated to support a Biologics License Application (BLA) submission under the FDA's Accelerated Approval program.

As of September 30, 2025, DBV Technologies reported cash and cash equivalents of $69.8 million, a substantial increase from $32.5 million at the end of 2024. The company has also entered into a Sales Agreement for an equity offering program, allowing it to raise up to $150 million through the sale of American Depositary Shares. This funding is expected to support ongoing development and commercialization efforts for the Viaskin Peanut patch. However, the company noted that its current cash reserves may not be sufficient to fund operations beyond the third quarter of 2026, raising concerns about its ability to continue as a going concern without additional financing.

Looking ahead, DBV Technologies remains focused on advancing its clinical programs and preparing for potential regulatory submissions. The company is actively pursuing various financing options, including additional sales under its ATM program and potential warrant exercises, to ensure it has the necessary capital to support its operations and product development initiatives.